Lighthouse Investment Partners LLC Lowers Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Lighthouse Investment Partners LLC lessened its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 63.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 80,000 shares of the company's stock after selling 139,971 shares during the period. Lighthouse Investment Partners LLC's holdings in Teva Pharmaceutical Industries were worth $1,763,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $44,000. Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $66,000. IFP Advisors Inc raised its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after buying an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its stake in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after buying an additional 949 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.08 during trading hours on Friday, reaching $16.95. 9,758,609 shares of the company traded hands, compared to its average volume of 9,995,809. The stock has a market capitalization of $19.22 billion, a P/E ratio of -11.69, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The business has a fifty day moving average price of $15.34 and a 200-day moving average price of $17.43.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same period in the prior year, the company earned $0.48 earnings per share. The firm's revenue was up 1.9% on a year-over-year basis. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of recent research reports. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Finally, UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $24.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.